TGFβ, a biological peptide under control: Latent forms and mechanisms of activation;TGFβ, un peptide biologique sous controle: formes latentes et mecanismes d'activation

Medecine/Sciences

Volumn 12, Issue 8-9, 1996, Pages 929-939

  Feige, Jean Jacques ^a   Quirin, Nicolas ^a   Souchelnitskiy, Sergiy ^a  

^a CEA GRENOBLE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 2 MACROGLOBULIN; TRANSFORMING GROWTH FACTOR BETA;

BIOSYNTHESIS; CELL DIFFERENTIATION; CELL GROWTH; COVALENT BOND; MOLECULAR BIOLOGY; MOLECULAR INTERACTION; PROTEIN DEGRADATION; REVIEW;

EID: 0029743295     PISSN: 07670974     EISSN: None     Source Type: Journal    
DOI: 10.4267/10608/850     Document Type: Review

References (54)

1. Roberts AB, Sporn MB. The transforming growth factor-βs. In: Sporn MB, Roberts AB, eds. Peptide growth factors and their receptors I. Berlin: Springer, 1990: 419-72.
2. Derynck R, Jarrett JA, Chen EY, Easton DH, Bell JR, Assoian RK, Roberts AB, Sporn MB, Goeddel DV. Human transforming growth factor-beta complementary DNA sequence and expression in normal and transformed cells. Nature 1985; 316: 701-5.
3. Massagué J, Attisiano L, Wrana JL. The TGFβ family and its composite receptors. Trends Cell Biol 1994; 4: 172-8.
4. Kingsley DM. The TGFβ superfamily: new members, new receptors, and new genetic tests of function in different organisms. Genes Dev 1994; 8: 133-46.
5. Roberts AB, Flanders KC, Kondaiah P, Thompson NL, Van Obberghen-Schilling E, Wakefield L, Rossi P, de Crombrugghe B, Heine U, Sporn MB. Transforming growth factor β : biochemistry and roles in embryogenesis, tissue repair and remodeling, and carcinogenesis. Rec Prog Horm Res 1988; 44: 157-97.
6. Akhurst RJ, FitzPatrick DR, Gatherer D, Lehnert SA, Millan FA. Transforming growth factor betas in mammalian embryogenesis. Prog Growth Factor Res 1990; 2: 153-68.
7. Kulkarni AR, Ward JM, Yaswen L, Mackall CL, Bauer SR, Huh CG, Gress RE, Karlsson S. Animal model. Transforming growth factor-β1 null mice. An animal model for inflammatory disorders. Am J Pathol 1995; 146: 264-75.
8. Ten Dijke P, Franzen P, Yamashita H, Ichijo H, Heldin CH, Miyazono K. Serine/ threonine kinase receptors. Prog Growth Factor Res 1994; 5: 55-72.
9. Cheifetz S, Bellon T, Calés C, Vera S, Bernabeu C, Massagué J, Letarte M. Endoglin is a component of the transforming growth factor-β receptor system in human endothelial cells. J Biol Chem 1992; 19027-30.
10. Feige JJ, Baird A. La crinopexie: un modèle décrivant les mécanismes qui régissent la biodisponibilité des facteurs de croissance. médecine/sciences 1992; 8: 805-10.
11. Lawrence DA, Pircher R, Krycève-Martinierie C, Jullien P. Normal embryo fibroblasts release transforming growth factors in a latent form. J Cell Physiol 1984; 121: 184-8.
12. Brown PD, Wakefield LM, Levinson AD, Sporn MB. Physicochemical activation of recombinant latent transforming growth factor-beta 1, 2, and 3. Growth Factors 1990; 3: 35-43.
13. 2-macroglobulin: a binding protein for TGFβ and various cytokines. Horm Res 1996; 45: 227-32.
14. O'Connor-McCourt M, Wakefield LM. Latent transforming growth factor-beta in serum. A specific complex with alpha 2-macroglobulin. J Biol. Chem 1987; 262: 14090-9.
15. 2-macroglobulin-cytokine interactions based on affinity of noncovalent association in solution under apparent equilibrium conditions. J Biol Chem 1994; 269: 153-40.
16. Strickland DK, Kounnas MZ, Argraves WS. LDL receptor-related protein : a multiligand receptor for lipoprotein and proteinase catabolism. FASEB J 1995; 9: 890-8.
17. McCaffrey TA, Falcone DJ, Brayton CF, Agarwel LA, Welt FG, Weksler BB. Transforming growth factor-beta activity is potentiated by heparin via dissociation of the transforming growth factor-beta alpha 2-macroglobulin inactive complex. J Cell Biol 1989; 109: 441-8.
18. 2-macroglobulin is caused by associated transforming growth factor β. Mol Cell Endocrinol 1992; 84: 243-51.
19. Gentry LE, Webb NR, Lim GJ, Brunner AM, Ranchalis JE, Twardzik DR, Lioubin MN, Marquardt H, Purchio AF. Type I transforming growth factor beta: amplified expression and secretion of mature and precursor polypeptides in Chinese hamster ovary cells. Mol Cell Biol 1987; 7: 3418-27.
20. Dubois CM, Laprise MH, Blanchette F, Gentry LE, Leduc R. Processing of transforming growth factor β1 precursor by human furin convertase. J Biol Chem 1995; 270: 10618-24.
21. Archer SJ, Bax A, Roberts AB, Sporn MB, Ogawa Y, Piez KA, Weatherbee JA, Tsang MLS, Lucas R, Zheng BL, Wenker J, Torchia DA. Transforming growth factor β1 : secondary structure as determined by heteronuclear magnetic resonance spectroscopy. Biochemistry 1993; 32: 1164-71.
22. Miyazono K, Ichijo H, Heldin CH. Transforming growth factor-β: latent forms, binding proteins and receptors. Growth Factors 1993; 8: 11-22.
23. Sha X, Yang L, Gentry LE. Identification and analysis of discrete functional domains in the pro region of pre-pro-transforming growth factor beta 1. J Cell Biol 1991; 114: 827-39.
24. Miller DM, Ogawa Y, Iwata KK, ten Dijke P, Purchio AF, Soloff MS, Gentry LE. Characterization of the binding of transforming growth factor β-1, β2, and β3 to recombinant β1-latency-associated peptide. Mol Endocrinol 1992; 6: 694-702.
25. Miyazono K, Heldin CH. Role for carbohydrate structures in TGF-beta latency. Nature 1989; 338: 158-60.
26. Miyazono K, Hellman U, Wernstedt C, Heldin CH. Latent high molecular weight complex of transforming growth factor beta 1. Purification from human platelets and structural characterization. J Biol Chem 1988; 263: 6407-15.
27. Kanzaki T, Olofsson A, Moren A, Wernstedt C, Hellman U, Miyazono K, Claesson-Welsh L, Heldin C-H. TGF-β1 binding protein: a component of the large latent complex of TGF-β1 with multiple repeat sequences. Cell 1990; 61: 1051-61.
28. Saharinen J, Taipale J, Keski-Oja J. Association of the small latent transforming growth factor-β with an eight cysteine repeat of its binding protein, LTBP-1. EMBO J 1996; 15: 245-53.
29. Dallas SL, Miyazono K, Skerry TM, Mundy GR, Bonewald LF. Dual role for the latent transforming growth factor-β binding protein in storage of latent TGF-β in the extracellular matrix and as a structural matrix protein. J Cell Biol 1995; 131: 539-49.
30. Flaumenhaft R, Abe M, Sato Y, Miyazono K, Harpel JG, Heldin CH, Rifkin DB. Role of the latent TGF-β binding protein in the activation of latent TGF-β by co cultures of endothelial and smooth muscle cells. J Cell Biol 1993; 120: 995-1002.
31. Olofsson A, Miyazono K, Kanzaki T, Colosetti P, Engstrom U, Heldin CH. Transforming growth factor-beta 1, -beta 2, and -beta 3 secreted by a human glioblastoma cell line. Identification of small and different forms of large latent complexes. J Biol Chem 1992; 267: 19482-88.
32. Bonewald LF, Wakefield L, Oreffo RO, Escobedo A, Twardzik DR, Mundy GR. Latent forms of transforming growth factor-beta (TGF beta) derived from bone culture: identification of a naturally occurring 100 kDa complex with similarity to recombinant latent TGF beta. Mol Endocrinol 1991; 5: 741-51.
33. Souchelnitskiy S, Chambaz EM, Feige JJ. Thrombospondins selectively activate one of two latent forms of transforming growth factor-β present in adrenocortical cell-conditioned medium. Endocrinology 1995; 136: 5118-26.
34. Oreffo ROC, Mundy GR, Seyedin SM, Bonewald LF. Activation of the bone-derived latent TGF beta complex by isolated osteoclasts. Biochem Biophys Res Commun 1989; 158: 817-23.
35. Harpel JG, Metz CN, Kojima S, Rifkin DB. Control of transforming growth factor-β activity: latency vs. activation. Prog Growth Factors Res 1992; 4: 321-35.
36. Lyons RM, Gentry LE, Purchio AF, Moses HL. Mechanism of activation of latent recombinant transforming growth factor beta 1 by plasmin. J Cell Biol 1990; 110: 1361-7.
37. Antonelli-Orlidge A, Saunders KB, Smith SR, D'Amore PA. An activated form of transforming growth factor beta is produced by cocultures of endothelial cells and pericytes. Proc Natl Acad Sci USA 1989; 86: 4544-8.
38. Sato Y, Rifkin DB. Inhibition of endothelial cell movement by pericytes and smooth muscle cells: activation of a latent transforming growth factor-beta 1-like molecule by plasmin during coculture. J Cell Biol 1989; 109: 309-15.
39. Kojima S, Harpel PC, Rifkin DB. Lipoprotein (a) inhibits the generation of transforming growth factor beta: an endogenous inhibitor of smooth muscle cell migration. J Cell Biol 1991; 113: 1439-45.
40. Grainger DJ, Kemp PR, Liu AC, Lawn RM, Metcalfe JC. Activation of transforming growth factor-β is inhibited in transgenic apolipoprotein (a) mice. Nature 1994; 370: 460-2.
41. Schultz-Cherry S, Murphy-Ullrich JE. Thrombospondin causes activation of latent transforming growth factor-β secreted by endothelial cells by a novel mechanism. J Cell Biol 1993; 122: 923-32.
42. Bornstein P, Sage EH. Thrombospondins. Meth Enzymol 1994; 245: 62-85.
43. Schulz-Cherry S, Ribeiro S, Gentry L, Murphy-Ullrich JE. Thrombospondin binds and activates the small and large forms of latent transforming growth factor-β in a chemically defined system. J Biol Chem 1994; 269: 26775-82.
44. Schulz-Cherry S, Chen H, Mosher DF, Misenheimer TM, Krutzsch HC, Roberts DD, Murphy-Ullrich JE. Regulation of transforming growth factor-β activation by discrete sequences of thrombospondin 1. J Biol Chem 1995; 270: 7304-10.
45. Pellerin S, Lafeuillade B, Scherrer N, Gagnon J, Shi DL, Chambaz EM, Feige JJ Corticotropin-induced secreted protein, an ACTH-induced protein secreted by adrenocortical cells, is structurally related to thrombospondins. J Biol Chem 1993; 268: 4304-10.
46. Feige JJ, Cochet C, Savona C, Shi DL, Keramidas M, Defaye G, Chambaz EM. Transforming growth factor β1: an autocrine regulator of adrenocortical steroidogenesis. Endocrine Res 1991; 17: 267-79.
47. Wahl SM. Transforming growth factor β: The good, the bad, and the ugly. J Exp Med 1994; 180: 1587-90.
48. Grainger DJ, Witchell CM, Metcalfe JC. Tamoxifen elevates transforming growth factor-β and suppresses diet-induced formation of lipid lesions in mouse aorta. Nature Med 1995; 1: 1067-73.
49. Beck LS, De Guzman L, Lee WP, Xu Y, Siegel MW, Amento EP. One systemic administration of transforming growth factor-beta 1 reverses age- and glucocorticoid-impaired wound healing. J Clin Invest 1993; 92: 2841-9.
50. Sporn MB, Roberts AB. A major advance in the use of growth factors to enhance wound healing. J Clin Invest 1993; 92: 2565-6.
51. Border WA, Noble NA. Transforming growth factor β in tissue fibrosis. N Engl J Med 1994; 331: 1286-92.
52. Noble NA, Harper JR, Border WA. In vivo interactions of TGT-β and extracellular matrix. Prog Growth Factor Res 1992; 4: 369-82.
53. Shah M, Foreman DM, Ferguson MWJ. Neutralisation of TGF-β1 and TGF-β2 or exogenous addition of TGF-β3 to cutaneous rat wounds reduces scarring. J Cell Sci 1995; 108: 985-1002.
54. Border WA, Noble NA. Targeting TGF-β for treatment of disease. Nature Med 1995; 1: 1000-1.